Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Jakubowski, Ann  [Clear All Filters]
2024
Krystel-Whittemore M, Petrova-Drus K, Ptashkin RN, Ewalt MD, Yao JJ, Liu Y, Zhu M, Benhamida J, Durham B, Kumar J, et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica. 2024.
2023
Nath K, Peterson K, Brown S, Devlin S, Rodriguez N, Barker J, Giralt S, Gyurkocza B, Jakubowski A, Papadopoulos E, et al. Reduced Intensity Compared to Non-myeloablative Conditioning in Patients with Non-Hodgkin Lymphoma undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Prockop SE, Hasan AN, Doubrovina E, Dahi PB, M Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao JJ, et al. Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. J Clin Invest. 2023.
2021
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
2018
Kamboj M, Cohen N, Huang Y-T, Kerpelev M, Jakubowski A, Sepkowitz KA, Papanicolaou GA, Seo SK. Impact of empiric treatment for vancomycin-resistant Enterococcus (VRE) in colonized patients early after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018.
Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
2015
Neofytos D, Huang Y-T, Cheng K, Cohen N, Perales M-A, Barker J, Giralt S, Jakubowski A, Papanicolaou G. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clin Infect Dis. 2015;61(suppl 6):S652-S661.